ROBERT FINDLEY: Open Payments
NPI 1881601102 · GAINESVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,087 in 57 payments from 17 companies in 2025. Trend: 2023 $905 · 2024 $824 · 2025 $1,087
Food & beverage: $1,087
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $247 |
| Vanda Pharmaceuticals Inc. | 10 | $180 |
| Janssen Pharmaceuticals, Inc | 4 | $114 |
| Teva Pharmaceuticals USA, Inc. | 5 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $83 |
| ABBVIE INC. | 3 | $67 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Lundbeck LLC | 1 | $25 |
Products named: REXULTI, FANAPT, CAPLYTA, INVEGA SUSTENNA, HETLIOZ, AUSTEDO XR, VRAYLAR, INGREZZA.
Industry payments across GA — which companies pay providers there.
